{
  "model": "gpt-oss-120b",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 1,
  "result": {
    "text": "Checklist of written output files:\n- output/study_overview.json\n- output/quantitative_findings.json\n- output/claim_audit.json\n- output/public_summary.json\n\nAll required JSON outputs have been created.",
    "thoughts": "",
    "steps": [
      {
        "step": 1,
        "modelVersion": "accounts/fireworks/models/gpt-oss-120b",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "TASK.md",
              "offset": null,
              "limit": null
            },
            "output": "L1: # Agent Task\nL2: \nL3: Task id: tumor-vaccine-ici\nL4: Task title: mRNA tumor sensitization for checkpoint blockade\nL5: Reference paper: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL6: Reference URL: https://www.nature.com/articles/s41586-025-09006-8\nL7: \nL8: ## Objective\nL9: Read the report and produce all required JSON outputs that satisfy their schemas.\nL10: \nL11: ## Inputs On Disk\nL12: - Report: `input/report.md`\nL13: - Schemas: in `schemas/`\nL14: \nL15: ## Required Outputs\nL16: - `output/study_overview.json` (schema: `schemas/study_overview.schema.json`)\nL17: - `output/quantitative_findings.json` (schema: `schemas/quantitative_findings.schema.json`)\nL18: - `output/claim_audit.json` (schema: `schemas/claim_audit.schema.json`)\nL19: - `output/public_summary.json` (schema: `schemas/public_summary.schema.json`)\nL20: \nL21: ## Constraints\nL22: - Do not invent source facts; derive calculations only from values in the report.\nL23: - Use line refs as `L<number>` where required.\nL24: - Where quotes are required, copy exact report snippets.\nL25: - For calculation outputs, line_refs must include every report line used for equations, constants, and numeric substitutions.\nL26: - Use relative paths only.\nL27: - Never use absolute paths.\nL28: - Never use `..` in paths.\nL29: - Write valid JSON only.\nL30: \nL31: ## Completion\nL32: Respond with a checklist of written output files.\nL33: After the checklist, stop. Do not call more tools.",
            "callId": "call_dUsAHlv5cAXE2S5uUNa3ES8l"
          }
        ],
        "usage": {
          "promptTokens": 518,
          "cachedTokens": 0,
          "responseTokens": 46,
          "totalTokens": 564
        },
        "costUsd": 0
      },
      {
        "step": 2,
        "modelVersion": "accounts/fireworks/models/gpt-oss-120b",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "schemas",
              "ignore": null,
              "file_filtering_options": null
            },
            "output": "claim_audit.schema.json\npublic_summary.schema.json\nquantitative_findings.schema.json\nstudy_overview.schema.json",
            "callId": "call_mJUauUtkD0cb1pPRjlJmsrKc"
          }
        ],
        "usage": {
          "promptTokens": 976,
          "cachedTokens": 517,
          "responseTokens": 57,
          "totalTokens": 1033
        },
        "costUsd": 0
      },
      {
        "step": 3,
        "modelVersion": "accounts/fireworks/models/gpt-oss-120b",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "input/report.md",
              "offset": null,
              "limit": null
            },
            "output": "L1: # Structured Paper Report: Tumor Sensitization by mRNA Vaccination\nL2: \nL3: ## Citation\nL4: - Title: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL5: - Journal: Nature\nL6: - Year: 2025\nL7: - DOI: 10.1038/s41586-025-09006-8\nL8: - Source URL: https://www.nature.com/articles/s41586-025-09006-8\nL9: \nL10: ## One-Paragraph Context\nL11: Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors remain non-responsive due to weak antigen presentation or poor immune priming. The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\nL12: \nL13: ## Study Design Snapshot\nL14: - Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\nL15: - Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\nL16: - Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\nL17: \nL18: ## Cohorts and Scenarios\nL19: 1. Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\nL20: 2. Mouse control cohort (vaccine only, ICI only, and vehicle): 84 tumor-bearing mice pooled across matched controls.\nL21: 3. Human retrospective metastatic cohort: 130 patients total.\nL22: 4. Human vaccinated subgroup: 43 patients.\nL23: 5. Human unvaccinated subgroup: 87 patients.\nL24: \nL25: ## Quantitative Findings\nL26: | Metric | Vaccine/Combination Arm | Comparator | Interpretation |\nL27: |---|---:|---:|---|\nL28: | Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\nL29: | Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\nL30: | Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\nL31: | Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\nL32: | PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\nL33: | Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\nL34: \nL35: ## Controls and Null/Conditional Results\nL36: - Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\nL37: - ICI-only treatment had limited activity in low-immunogenic baseline settings.\nL38: - Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\nL39: - Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\nL40: \nL41: ## Mechanistic Chain Proposed by Authors\nL42: 1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\nL43: 2. Interferon-associated antigen processing and presentation pathways increase.\nL44: 3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\nL45: 4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\nL46: 5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\nL47: \nL48: ## Caveats and Threats to Validity\nL49: - The human analysis is retrospective and non-randomized; residual confounding is likely.\nL50: - Vaccination timing relative to ICI initiation varied across patients.\nL51: - Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\nL52: - Mouse model effects may not map one-to-one to all human tumors.\nL53: - Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\nL54: \nL55: ## Practical Takeaway\nL56: The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.",
            "callId": "call_y8NxKlLkKzv0kVObmJ4vKxOl"
          }
        ],
        "usage": {
          "promptTokens": 1048,
          "cachedTokens": 0,
          "responseTokens": 55,
          "totalTokens": 1103
        },
        "costUsd": 0
      },
      {
        "step": 4,
        "modelVersion": "accounts/fireworks/models/gpt-oss-120b",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/study_overview.schema.json",
              "offset": null,
              "limit": null
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-study_overview\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"paper\": {\nL7:       \"type\": \"object\",\nL8:       \"properties\": {\nL9:         \"title\": {\nL10:           \"type\": \"string\",\nL11:           \"minLength\": 10\nL12:         },\nL13:         \"doi\": {\nL14:           \"type\": \"string\",\nL15:           \"pattern\": \"^10\\\\.\"\nL16:         },\nL17:         \"publication_year\": {\nL18:           \"type\": \"integer\",\nL19:           \"minimum\": 1900,\nL20:           \"maximum\": 2100\nL21:         },\nL22:         \"domain\": {\nL23:           \"type\": \"string\",\nL24:           \"enum\": [\nL25:             \"oncology-immunology\",\nL26:             \"exoplanet-atmospheres\",\nL27:             \"climate-science\",\nL28:             \"neuroscience\",\nL29:             \"other\"\nL30:           ]\nL31:         },\nL32:         \"study_type\": {\nL33:           \"type\": \"string\",\nL34:           \"enum\": [\nL35:             \"preclinical+retrospective\",\nL36:             \"observational-astronomy\",\nL37:             \"randomized-trial\",\nL38:             \"simulation\",\nL39:             \"mixed\"\nL40:           ]\nL41:         }\nL42:       },\nL43:       \"required\": [\nL44:         \"title\",\nL45:         \"doi\",\nL46:         \"publication_year\",\nL47:         \"domain\",\nL48:         \"study_type\"\nL49:       ],\nL50:       \"additionalProperties\": false\nL51:     },\nL52:     \"core_question\": {\nL53:       \"type\": \"string\",\nL54:       \"minLength\": 20\nL55:     },\nL56:     \"datasets_or_cohorts\": {\nL57:       \"type\": \"array\",\nL58:       \"items\": {\nL59:         \"type\": \"object\",\nL60:         \"properties\": {\nL61:           \"id\": {\nL62:             \"type\": \"string\",\nL63:             \"pattern\": \"^[a-z0-9-]+$\"\nL64:           },\nL65:           \"label\": {\nL66:             \"type\": \"string\",\nL67:             \"minLength\": 3\nL68:           },\nL69:           \"sample_size_or_observations\": {\nL70:             \"type\": \"string\",\nL71:             \"minLength\": 1\nL72:           },\nL73:           \"description\": {\nL74:             \"type\": \"string\",\nL75:             \"minLength\": 20\nL76:           }\nL77:         },\nL78:         \"required\": [\nL79:           \"id\",\nL80:           \"label\",\nL81:           \"sample_size_or_observations\",\nL82:           \"description\"\nL83:         ],\nL84:         \"additionalProperties\": false\nL85:       },\nL86:       \"minItems\": 2,\nL87:       \"maxItems\": 8\nL88:     },\nL89:     \"major_limitations\": {\nL90:       \"type\": \"array\",\nL91:       \"items\": {\nL92:         \"type\": \"string\",\nL93:         \"minLength\": 12\nL94:       },\nL95:       \"minItems\": 3,\nL96:       \"maxItems\": 8\nL97:     }\nL98:   },\nL99:   \"required\": [\nL100:     \"paper\",\nL101:     \"core_question\",\nL102:     \"datasets_or_cohorts\",\nL103:     \"major_limitations\"\nL104:   ],\nL105:   \"additionalProperties\": false\nL106: }",
            "callId": "call_pFxQTqHn0HJr65ApwHF5H4a4"
          }
        ],
        "usage": {
          "promptTokens": 2160,
          "cachedTokens": 0,
          "responseTokens": 53,
          "totalTokens": 2213
        },
        "costUsd": 0
      },
      {
        "step": 5,
        "modelVersion": "accounts/fireworks/models/gpt-oss-120b",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/quantitative_findings.schema.json",
              "offset": null,
              "limit": null
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-quantitative_findings\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"findings\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^Q[0-9]{2}$\"\nL14:           },\nL15:           \"metric\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 6\nL18:           },\nL19:           \"value\": {\nL20:             \"type\": \"string\",\nL21:             \"minLength\": 1\nL22:           },\nL23:           \"comparator_or_baseline\": {\nL24:             \"type\": \"string\",\nL25:             \"minLength\": 1\nL26:           },\nL27:           \"interpretation\": {\nL28:             \"type\": \"string\",\nL29:             \"minLength\": 12\nL30:           },\nL31:           \"evidence_line_refs\": {\nL32:             \"type\": \"array\",\nL33:             \"items\": {\nL34:               \"type\": \"string\",\nL35:               \"pattern\": \"^L[1-9]\\\\d*$\"\nL36:             },\nL37:             \"minItems\": 1,\nL38:             \"maxItems\": 3\nL39:           }\nL40:         },\nL41:         \"required\": [\nL42:           \"id\",\nL43:           \"metric\",\nL44:           \"value\",\nL45:           \"comparator_or_baseline\",\nL46:           \"interpretation\",\nL47:           \"evidence_line_refs\"\nL48:         ],\nL49:         \"additionalProperties\": false\nL50:       },\nL51:       \"minItems\": 5,\nL52:       \"maxItems\": 14\nL53:     },\nL54:     \"controls_or_null_results\": {\nL55:       \"type\": \"array\",\nL56:       \"items\": {\nL57:         \"type\": \"object\",\nL58:         \"properties\": {\nL59:           \"statement\": {\nL60:             \"type\": \"string\",\nL61:             \"minLength\": 10\nL62:           },\nL63:           \"evidence_line_ref\": {\nL64:             \"$ref\": \"#/definitions/schemas-quantitative_findings/properties/findings/items/properties/evidence_line_refs/items\"\nL65:           }\nL66:         },\nL67:         \"required\": [\nL68:           \"statement\",\nL69:           \"evidence_line_ref\"\nL70:         ],\nL71:         \"additionalProperties\": false\nL72:       },\nL73:       \"minItems\": 2,\nL74:       \"maxItems\": 10\nL75:     }\nL76:   },\nL77:   \"required\": [\nL78:     \"findings\",\nL79:     \"controls_or_null_results\"\nL80:   ],\nL81:   \"additionalProperties\": false\nL82: }",
            "callId": "call_Gzb0x8fWI08rWP7S94rgfQlQ"
          }
        ],
        "usage": {
          "promptTokens": 3121,
          "cachedTokens": 0,
          "responseTokens": 52,
          "totalTokens": 3173
        },
        "costUsd": 0
      },
      {
        "step": 6,
        "modelVersion": "accounts/fireworks/models/gpt-oss-120b",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/claim_audit.schema.json",
              "offset": null,
              "limit": null
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-claim_audit\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"claims\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"claim_id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^C[0-9]{2}$\"\nL14:           },\nL15:           \"claim\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 20\nL18:           },\nL19:           \"strength\": {\nL20:             \"type\": \"string\",\nL21:             \"enum\": [\nL22:               \"strong\",\nL23:               \"moderate\",\nL24:               \"tentative\"\nL25:             ]\nL26:           },\nL27:           \"evidence\": {\nL28:             \"type\": \"array\",\nL29:             \"items\": {\nL30:               \"type\": \"object\",\nL31:               \"properties\": {\nL32:                 \"quote\": {\nL33:                   \"type\": \"string\",\nL34:                   \"minLength\": 10\nL35:                 },\nL36:                 \"line_ref\": {\nL37:                   \"type\": \"string\",\nL38:                   \"pattern\": \"^L[1-9]\\\\d*$\"\nL39:                 }\nL40:               },\nL41:               \"required\": [\nL42:                 \"quote\",\nL43:                 \"line_ref\"\nL44:               ],\nL45:               \"additionalProperties\": false\nL46:             },\nL47:             \"minItems\": 2,\nL48:             \"maxItems\": 3\nL49:           },\nL50:           \"caveat\": {\nL51:             \"type\": \"string\",\nL52:             \"minLength\": 20\nL53:           }\nL54:         },\nL55:         \"required\": [\nL56:           \"claim_id\",\nL57:           \"claim\",\nL58:           \"strength\",\nL59:           \"evidence\",\nL60:           \"caveat\"\nL61:         ],\nL62:         \"additionalProperties\": false\nL63:       },\nL64:       \"minItems\": 4,\nL65:       \"maxItems\": 10\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"claims\"\nL70:   ],\nL71:   \"additionalProperties\": false\nL72: }",
            "callId": "call_vZztspDsrVS3Jx2E1yBcDOX0"
          }
        ],
        "usage": {
          "promptTokens": 3909,
          "cachedTokens": 0,
          "responseTokens": 61,
          "totalTokens": 3970
        },
        "costUsd": 0
      },
      {
        "step": 7,
        "modelVersion": "accounts/fireworks/models/gpt-oss-120b",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/public_summary.schema.json",
              "offset": null,
              "limit": null
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-public_summary\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"headline\": {\nL7:       \"type\": \"string\",\nL8:       \"minLength\": 20,\nL9:       \"maxLength\": 120\nL10:     },\nL11:     \"plain_language_summary\": {\nL12:       \"type\": \"string\",\nL13:       \"minLength\": 180,\nL14:       \"maxLength\": 1200\nL15:     },\nL16:     \"what_is_new\": {\nL17:       \"type\": \"array\",\nL18:       \"items\": {\nL19:         \"type\": \"string\",\nL20:         \"minLength\": 20\nL21:       },\nL22:       \"minItems\": 3,\nL23:       \"maxItems\": 3\nL24:     },\nL25:     \"why_caution_is_needed\": {\nL26:       \"type\": \"array\",\nL27:       \"items\": {\nL28:         \"type\": \"string\",\nL29:         \"minLength\": 20\nL30:       },\nL31:       \"minItems\": 3,\nL32:       \"maxItems\": 5\nL33:     },\nL34:     \"glossary\": {\nL35:       \"type\": \"array\",\nL36:       \"items\": {\nL37:         \"type\": \"object\",\nL38:         \"properties\": {\nL39:           \"term\": {\nL40:             \"type\": \"string\",\nL41:             \"minLength\": 2\nL42:           },\nL43:           \"definition\": {\nL44:             \"type\": \"string\",\nL45:             \"minLength\": 20,\nL46:             \"maxLength\": 220\nL47:           }\nL48:         },\nL49:         \"required\": [\nL50:           \"term\",\nL51:           \"definition\"\nL52:         ],\nL53:         \"additionalProperties\": false\nL54:       },\nL55:       \"minItems\": 4,\nL56:       \"maxItems\": 8\nL57:     },\nL58:     \"open_questions\": {\nL59:       \"type\": \"array\",\nL60:       \"items\": {\nL61:         \"type\": \"string\",\nL62:         \"minLength\": 20\nL63:       },\nL64:       \"minItems\": 3,\nL65:       \"maxItems\": 6\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"headline\",\nL70:     \"plain_language_summary\",\nL71:     \"what_is_new\",\nL72:     \"why_caution_is_needed\",\nL73:     \"glossary\",\nL74:     \"open_questions\"\nL75:   ],\nL76:   \"additionalProperties\": false\nL77: }",
            "callId": "call_XbdC2DnzCdAFTVAtSW824Td9"
          }
        ],
        "usage": {
          "promptTokens": 4564,
          "cachedTokens": 0,
          "responseTokens": 38,
          "totalTokens": 4602
        },
        "costUsd": 0
      },
      {
        "step": 8,
        "modelVersion": "accounts/fireworks/models/gpt-oss-120b",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/study_overview.json",
              "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral mRNA vaccination sensitize tumors to immune checkpoint blockade and improve therapeutic outcomes?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"c1\",\n      \"label\": \"mouse efficacy\",\n      \"sample_size_or_observations\": \"78 mice\",\n      \"description\": \"Combination of intratumoral mRNA vaccine and anti‑PD‑L1 treatment across multiple murine tumor models (L19-L20).\"\n    },\n    {\n      \"id\": \"c2\",\n      \"label\": \"mouse control\",\n      \"sample_size_or_observations\": \"84 mice\",\n      \"description\": \"Matched control groups receiving vaccine only, ICI only, or vehicle (L19-L20).\"\n    },\n    {\n      \"id\": \"c3\",\n      \"label\": \"human retrospective cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"Metastatic cancer patients treated with ICIs, stratified by prior SARS‑CoV‑2 mRNA vaccination status (L21-L23).\"\n    },\n    {\n      \"id\": \"c4\",\n      \"label\": \"human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subset of the retrospective cohort who received an mRNA vaccine before ICI (L22-L23).\"\n    },\n    {\n      \"id\": \"c5\",\n      \"label\": \"human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Subset of the retrospective cohort without prior mRNA vaccination (L22-L23).\"\n    }\n  ],\n  \"major_limitations\": [\n    \"Human analysis is retrospective and non‑randomized, introducing potential confounding (L48-L51).\",\n    \"Vaccination timing relative to ICI initiation varied among patients (L50-L51).\",\n    \"Mouse model findings may not translate directly to diverse human tumor types (L52-L53).\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/study_overview.json",
            "callId": "call_WKFSCJTbiSikQXEcjnpbNcS5"
          }
        ],
        "usage": {
          "promptTokens": 5292,
          "cachedTokens": 1047,
          "responseTokens": 2236,
          "totalTokens": 7528
        },
        "costUsd": 0
      },
      {
        "step": 9,
        "modelVersion": "accounts/fireworks/models/gpt-oss-120b",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L35\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json",
            "callId": "call_Bi9DUA6EAbmuP3Q5J3gqKjW8"
          }
        ],
        "usage": {
          "promptTokens": 5910,
          "cachedTokens": 3908,
          "responseTokens": 1582,
          "totalTokens": 7492
        },
        "costUsd": 0
      },
      {
        "step": 10,
        "modelVersion": "accounts/fireworks/models/gpt-oss-120b",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling, initiating downstream antitumor immunity.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        },\n        {\n          \"quote\": \"2. Interferon-associated antigen processing and presentation pathways increase.\",\n          \"line_ref\": \"L43\"\n        }\n      ],\n      \"caveat\": \"Evidence is based on preclinical murine models and may not fully translate to humans.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"mRNA vaccination broadens the tumor immunopeptidome, increasing the fraction of tumor proteins presented on MHC molecules.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\n          \"line_ref\": \"L29\"\n        }\n      ],\n      \"caveat\": \"The magnitude of expansion is measured in murine tumors and may differ in human cancers.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"PD‑L1 expression in tumor tissue increases after mRNA vaccination, enhancing the targetability of checkpoint blockade.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable\",\n          \"line_ref\": \"L32\"\n        },\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"PD‑L1 up‑regulation may reflect an adaptive resistance mechanism rather than a purely beneficial effect.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Combining intratumoral mRNA vaccination with anti‑PD‑L1 therapy improves tumor control in mice and is associated with improved survival in a retrospective human cohort.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        }\n      ],\n      \"caveat\": \"Human evidence is retrospective, non‑randomized, and subject to confounding factors.\"\n    }\n  ]\n}"
            },
            "output": "Successfully wrote file: output/claim_audit.json",
            "callId": "call_0izH4HY2QWvtrdHds6MbPa9C"
          }
        ],
        "usage": {
          "promptTokens": 6621,
          "cachedTokens": 0,
          "responseTokens": 1274,
          "totalTokens": 7895
        },
        "costUsd": 0
      },
      {
        "step": 11,
        "modelVersion": "accounts/fireworks/models/gpt-oss-120b",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json",
            "callId": "call_6CHDMks0HNnbKSzne5ZIx0iq"
          }
        ],
        "usage": {
          "promptTokens": 7470,
          "cachedTokens": 975,
          "responseTokens": 1364,
          "totalTokens": 8834
        },
        "costUsd": 0
      },
      {
        "step": 12,
        "modelVersion": "accounts/fireworks/models/gpt-oss-120b",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L35\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json",
            "callId": "call_TMqaKTGgvrPkhxSH2MYKM2i9"
          }
        ],
        "usage": {
          "promptTokens": 8181,
          "cachedTokens": 0,
          "responseTokens": 1533,
          "totalTokens": 9714
        },
        "costUsd": 0
      },
      {
        "step": 13,
        "modelVersion": "accounts/fireworks/models/gpt-oss-120b",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"Intratumoral mRNA vaccines boost checkpoint inhibitor effectiveness but need human trials\",\n  \"plain_language_summary\": \"The researchers tested whether delivering an mRNA vaccine directly into mouse tumors could make the tumours more visible to the immune system and therefore respond better to drugs that block the PD‑L1 checkpoint. In several mouse models the vaccine increased interferon signals, broadened the range of tumour proteins presented on MHC‑I molecules and raised PD‑L1 levels, leading to stronger tumour control when combined with anti‑PD‑L1 therapy. A retrospective analysis of 130 metastatic cancer patients showed that those who had received a SARS‑CoV‑2 mRNA vaccine before starting checkpoint blockade survived longer (p=0.01). However, the human data are observational, the timing of vaccination varied, and mouse results may not translate to all human cancers. The study suggests a promising biological strategy but calls for prospective, randomised trials before clinical recommendations.\",\n  \"what_is_new\": [\n    \"mRNA vaccination directly inside tumours expands the immunopeptidome, exposing more tumour antigens to immune cells.\",\n    \"Type I interferon response scores rise sharply after intratumoral mRNA vaccination, indicating potent innate activation.\",\n    \"Retrospective human patients with prior SARS‑CoV‑2 mRNA vaccination showed improved survival under checkpoint blockade (p=0.01).\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human survival benefit comes from a non‑randomised, retrospective cohort, which may be confounded by other factors.\",\n    \"Vaccination timing relative to immunotherapy varied among patients, making causal inference uncertain.\",\n    \"Mouse tumour models do not capture the full diversity of human cancers, so results may not be generalisable.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A therapeutic that delivers messenger RNA encoding antigens, prompting cells to produce the antigen and stimulate an immune response.\"\n    },\n    {\n      \"term\": \"checkpoint inhibitor\",\n      \"definition\": \"A drug that blocks proteins such as PD‑L1, releasing the brakes on T‑cells to allow them to attack cancer cells more effectively.\"\n    },\n    {\n      \"term\": \"immunopeptidome\",\n      \"definition\": \"The complete set of peptide fragments displayed on a cell's MHC molecules, representing the antigens presented to T‑cells.\"\n    },\n    {\n      \"term\": \"type I interferon\",\n      \"definition\": \"A family of cytokines (e.g., IFN‑α, IFN‑β) produced during viral sensing that enhance antigen presentation and immune activation.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Will intratumoral mRNA vaccination improve outcomes in prospective randomised human trials?\",\n    \"What is the optimal timing and dosing schedule for combining mRNA vaccines with checkpoint inhibitors?\",\n    \"Can this strategy be effective across diverse tumour types beyond the preclinical models tested?\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_2996EiwmQqLXuCLYtK4rtmBl"
          }
        ],
        "usage": {
          "promptTokens": 8892,
          "cachedTokens": 0,
          "responseTokens": 1100,
          "totalTokens": 9992
        },
        "costUsd": 0
      },
      {
        "step": 14,
        "modelVersion": "accounts/fireworks/models/gpt-oss-120b",
        "text": "Checklist of written output files:\n- output/study_overview.json\n- output/quantitative_findings.json\n- output/claim_audit.json\n- output/public_summary.json\n\nAll required JSON outputs have been created.",
        "toolCalls": [],
        "usage": {
          "promptTokens": 9629,
          "cachedTokens": 0,
          "responseTokens": 49,
          "totalTokens": 9678
        },
        "costUsd": 0
      }
    ],
    "totalCostUsd": 0
  }
}
